I think that is exactly correct. The health economics would be potentially very valuable.
I dont think the study has failed in its entirety just yet.
They have all these üseless"vials that could be used to do a very cheap trial. A second stage.
Get an equal number of patients as a third arm. The Margolis 1 ulcers with VF001 alone. No standard of care and see if it gives the same result? (Unless this was the vitrocard study in which case they dont need to repeat it but simply add it to get the health economics justification and the CE mark).
Also
Look at all the patients at 6 months and see if any ulcers have recurred? Did VF001 lay a better scaffold? lower recurrence after treatment? Maybe cheap to check and not much to lose!
Could see it be worth a 10million dollar company in no time...
FTT Price at posting:
0.3¢ Sentiment: None Disclosure: Held
